The osteoporosis-associated fracture is a significant cause of morbidity and mortality, particularly in the developed countries. In the treatment of osteoporosis-associated fracture, it is essential to initiate adequate treatment of the underlying disease, i.e., osteoporosis. Because in most cases osteoporosis is diagnosed at the time of fracture occurrence with anti-osteoporosis medication prescribed, information on the influence of anti-osteoporosis drugs on fracture healing is essential. The anti-osteoporosis agents, such as bisphosphonate and calcitonin, has been proved to delay callus remodeling, although restoration of mechanical strength of fractured bone is not impaired. Sintered dicalcium pyrophosphate (SDCP), a pyrophosphate analog developed by Lin et al, was proven to be bone-biocompatible both in in vivo animal model and in vitro cell culture model. In ovariectomized rats, SDCP increased bone mass by inducing osteoclasts apoptosis. The effects of SDCP were comparable to those observed for alendronate, a bisphosphonate commonly used in clinical medicine. Whether the patients with osteoporosis-associated fractures should consider discontinuing anti-resorptive treatment or not is still not solved. The purpose of this study is to investigate the effect of SDCP on the fracture healing and the effect on the mechanical properties of callus. In this study, the effect of SDCP was evaluated in a rat fracture model compared with that of a powerful anti-resorptive agent such as alendronate and calcitonin.
|Effective start/end date||8/1/13 → 7/31/14|
- Sintered Dicalcium Pyrophosphate (SDCP)
- Bone healing
- Bone remodeling